CN105073197B - 抗cd20抗体和pi3激酶选择性抑制剂的组合 - Google Patents

抗cd20抗体和pi3激酶选择性抑制剂的组合 Download PDF

Info

Publication number
CN105073197B
CN105073197B CN201380069143.1A CN201380069143A CN105073197B CN 105073197 B CN105073197 B CN 105073197B CN 201380069143 A CN201380069143 A CN 201380069143A CN 105073197 B CN105073197 B CN 105073197B
Authority
CN
China
Prior art keywords
antibody
fluoro
compound
cells
ublituximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380069143.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105073197A (zh
Inventor
迈克尔·魏斯
哈里·米斯金
彼得·斯波尔泰利
斯瓦鲁普·库马尔·V·S·瓦卡拉恩卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhizen Pharmaceuticals AG
LFB SA
TG Therapeutics Inc
Original Assignee
Rhizen Pharmaceuticals AG
LFB SA
TG Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54264181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105073197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals AG, LFB SA, TG Therapeutics Inc filed Critical Rhizen Pharmaceuticals AG
Priority to CN201910562572.1A priority Critical patent/CN110269941A/zh
Publication of CN105073197A publication Critical patent/CN105073197A/zh
Application granted granted Critical
Publication of CN105073197B publication Critical patent/CN105073197B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380069143.1A 2012-11-02 2013-11-01 抗cd20抗体和pi3激酶选择性抑制剂的组合 Expired - Fee Related CN105073197B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910562572.1A CN110269941A (zh) 2012-11-02 2013-11-01 抗cd20抗体和pi3激酶选择性抑制剂的组合

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN4595/CHE/2012 2012-11-02
IN4595CH2012 2012-11-02
US201361771812P 2013-03-02 2013-03-02
US61/771,812 2013-03-02
PCT/US2013/067956 WO2014071125A1 (en) 2012-11-02 2013-11-01 Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910562572.1A Division CN110269941A (zh) 2012-11-02 2013-11-01 抗cd20抗体和pi3激酶选择性抑制剂的组合

Publications (2)

Publication Number Publication Date
CN105073197A CN105073197A (zh) 2015-11-18
CN105073197B true CN105073197B (zh) 2019-06-28

Family

ID=54264181

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910562572.1A Pending CN110269941A (zh) 2012-11-02 2013-11-01 抗cd20抗体和pi3激酶选择性抑制剂的组合
CN201380069143.1A Expired - Fee Related CN105073197B (zh) 2012-11-02 2013-11-01 抗cd20抗体和pi3激酶选择性抑制剂的组合

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910562572.1A Pending CN110269941A (zh) 2012-11-02 2013-11-01 抗cd20抗体和pi3激酶选择性抑制剂的组合

Country Status (22)

Country Link
US (3) US9694071B2 (enExample)
EP (3) EP2914343B1 (enExample)
JP (1) JP6437441B2 (enExample)
KR (2) KR102341275B1 (enExample)
CN (2) CN110269941A (enExample)
AU (3) AU2013337733B2 (enExample)
BR (1) BR112015009879A8 (enExample)
CA (1) CA2890176C (enExample)
CL (1) CL2015001124A1 (enExample)
CY (1) CY1123938T1 (enExample)
DK (1) DK3150256T3 (enExample)
EA (1) EA030745B1 (enExample)
IL (1) IL238564B (enExample)
LT (1) LT3150256T (enExample)
MX (2) MX375325B (enExample)
NZ (1) NZ708249A (enExample)
PL (1) PL3150256T3 (enExample)
RS (1) RS60844B1 (enExample)
SG (2) SG11201503393SA (enExample)
SI (1) SI3150256T1 (enExample)
SM (1) SMT202000543T1 (enExample)
WO (1) WO2014071125A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2890105C (en) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
KR102499191B1 (ko) 2016-03-18 2023-02-13 프레드 허친슨 캔서 센터 Cd20 면역요법을 위한 조성물 및 방법
BR112018074238A2 (pt) * 2016-05-27 2019-04-16 Tg Therapeutics, Inc. combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
BR112019004185A2 (pt) * 2016-09-09 2019-09-03 Lab Francais Du Fractionnement combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MA49921A (fr) * 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
CN114891005B (zh) * 2022-03-30 2024-01-19 武汉九州钰民医药科技有限公司 一种乌帕利斯对甲苯磺酸盐的制备工艺
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
AU2023281714A1 (en) * 2022-06-01 2024-12-19 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anti-cd20 antibody compositions
WO2025174079A1 (ko) * 2024-02-13 2025-08-21 연세대학교 산학협력단 항-cd20 항체 및 pikfyve의 억제제를 유효성분으로 포함하는 림프종의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101115772A (zh) * 2004-12-15 2008-01-30 分馏及生物技术法国实验室 针对b型淋巴造血增殖的细胞毒性抗体
CN101437956A (zh) * 2006-03-07 2009-05-20 国立大学法人大阪大学 人源化抗cd20单克隆抗体
WO2010014595A2 (en) * 2008-07-31 2010-02-04 The Ohio State University Research Foundation Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
CN104470923A (zh) * 2012-07-04 2015-03-25 理森制药股份公司 选择性PI3K δ抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU8619698A (en) 1997-07-25 1999-02-16 Ban C. H. Tsui Devices, systems and methods for determining proper placement of epidural catheters
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
CN102369011A (zh) * 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
PT2496567T (pt) * 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101115772A (zh) * 2004-12-15 2008-01-30 分馏及生物技术法国实验室 针对b型淋巴造血增殖的细胞毒性抗体
CN101437956A (zh) * 2006-03-07 2009-05-20 国立大学法人大阪大学 人源化抗cd20单克隆抗体
WO2010014595A2 (en) * 2008-07-31 2010-02-04 The Ohio State University Research Foundation Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
CN104470923A (zh) * 2012-07-04 2015-03-25 理森制药股份公司 选择性PI3K δ抑制剂

Also Published As

Publication number Publication date
US20200323981A1 (en) 2020-10-15
DK3150256T3 (da) 2020-08-24
MX2020009919A (es) 2020-10-14
LT3150256T (lt) 2020-11-10
BR112015009879A2 (enExample) 2014-05-08
KR20200136498A (ko) 2020-12-07
SG10201704511RA (en) 2017-07-28
CN110269941A (zh) 2019-09-24
JP6437441B2 (ja) 2018-12-12
MX2015005555A (es) 2015-11-30
US20150290317A1 (en) 2015-10-15
AU2013337733A1 (en) 2015-06-04
US10729768B2 (en) 2020-08-04
EP2914343B1 (en) 2019-03-06
KR102341275B1 (ko) 2021-12-21
MX375325B (es) 2025-03-06
CY1123938T1 (el) 2022-03-24
EP2914343A1 (en) 2015-09-09
NZ708249A (en) 2019-03-29
CN105073197A (zh) 2015-11-18
AU2018203579B2 (en) 2020-02-27
EA201590866A1 (ru) 2015-12-30
KR20150084885A (ko) 2015-07-22
SG11201503393SA (en) 2015-06-29
EP3756686A1 (en) 2020-12-30
CA2890176A1 (en) 2014-05-08
EA030745B1 (ru) 2018-09-28
RS60844B1 (sr) 2020-10-30
SMT202000543T1 (it) 2020-11-10
US20170304441A1 (en) 2017-10-26
AU2020203417A1 (en) 2020-06-11
SI3150256T1 (sl) 2021-03-31
JP2016505515A (ja) 2016-02-25
EP3150256B1 (en) 2020-07-15
CA2890176C (en) 2021-12-14
KR102185175B1 (ko) 2020-12-02
PL3150256T3 (pl) 2021-02-08
AU2018203579A1 (en) 2018-06-14
IL238564A0 (en) 2015-06-30
EP3150256A1 (en) 2017-04-05
IL238564B (en) 2020-11-30
CL2015001124A1 (es) 2016-01-08
AU2013337733B2 (en) 2018-03-08
US9694071B2 (en) 2017-07-04
WO2014071125A1 (en) 2014-05-08
BR112015009879A8 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
CN105073197B (zh) 抗cd20抗体和pi3激酶选择性抑制剂的组合
TWI762487B (zh) 抗-b7-h3抗體及抗體藥物結合物
US20210169878A1 (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
EP3303399A1 (en) Methods of treating cancer using anti-ox40 antibodies
WO2019232467A1 (en) Pharmacodynamic biomarkers for the treatment of cancer with a cdk8/19 inhibitor
AU2023221516A1 (en) Combination therapies for treatment of cancer comprising b7-h4 antibody drug conjugate
JP2022514832A (ja) 抗ｔｉｍ－３抗体とその利用
HK40043941A (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
ES2813343T3 (es) Combinación de anticuerpo anti-CD20 e inhibidor selectivo de PI3 quinasa
HK1231798A1 (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
HK1231798B (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
US20220143026A1 (en) Triple combination to treat b-cell malignancies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190628